###begin article-title 0
Adenosine Transporter ENT4 Is a Direct Target of EWS/WT1 Translocation Product and Is Highly Expressed in Desmoplastic Small Round Cell Tumor
###end article-title 0
###begin p 1
Conceived and designed the experiments: SL DH JW. Performed the experiments: SL HL GS LB LX. Analyzed the data: SL HL LB LX. Contributed reagents/materials/analysis tools: WG. Wrote the paper: SL HL JW.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 234 237 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive malignancy that affects mainly adolescents and young adults. A defining characteristic of DSRCT is a specific chromosomal translocation, t(11;22)(p13;q12), that fuses EWS with WT1, leading to a production of two isoforms of chimeric transcription factor, EWS/WT1(-KTS) and EWS/WT1(+KTS). The chimeric proteins are thought to play critical roles in various stages of oncogenesis through aberrant transcription of different genes, but only a few of these genes have been identified.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
We report the identification of a new target of EWS/WT1, ENT4 (equilibrative nucleoside transporter 4) which encodes a pH-dependent adenosine transporter. ENT4 is transcriptionally activated by both isoforms of EWS/WT1 as evidenced by promoter-reporter and chromatin immunoprecipitation (ChIP) analyses. Furthermore, ENT4 is highly and specifically expressed in primary tumors of DSRCT as well as in a DSRCT cell line, JN-DSRCT-1. Treatment of JN-DSRCT-1 cells with adenosine analogs, such as 2-chloro-2'-deoxyadenosine (2-CdA), resulted in an increased cytotoxic response in dose- and pH-dependent manner.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
Our detailed analyses of a novel target of EWS/WT1 in DSRCT reveal an insight into the oncogenic mechanism of EWS-fusion chromosomal translocation gene products and provide a new marker for DSRCT. Furthermore, identification of ENT4 as a highly expressed transcript in DSRCT may represent an attractive pathway for targeting chemotherapeutic drugs into DSRCT.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gerald1">[1]</xref>
###xml 255 258 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lae1">[3]</xref>
###xml 445 448 445 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gerald3">[4]</xref>
###xml 741 744 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 815 818 815 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 818 821 818 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gerald4">[5]</xref>
###xml 823 826 823 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Ladanyi1">[6]</xref>
Desmoplastic small round cell tumor (DSRCT) is a rare and poorly understood neoplasm with extremely poor prognosis. Tumors are frequently found in the serosal surface of abdomen and pelvis, although tumors arising from other sites have been described [1]-[3]. It is characterized histologically by solid nests of small neoplastic cells surrounded by dense stromal components consisting of fibroblasts and hyperplastic blood vessels (reviewed in [4]). The tumor cells are positive for epithelial, mesenchymal, and neural markers, thereby confounding the tumor cell origin. Genetic studies revealed that all cases of DSRCT harbor the t(11;22)(p13;q12) translocation, leading to a fusion of the N-terminal domain (NTD) of Ewing's sarcoma gene (EWS) to the C-terminal DNA binding domain of Wilms tumor suppressor gene, WT1[5], [6]. This unique chromosomal translocation provides the definitive molecular diagnosis of DSRCT and creates an aberrant transcription factor, EWS/WT1, which underlies the oncogenesis of DSRCT.
###end p 9
###begin p 10
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLI-1</italic>
###xml 184 187 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Delattre1">[7]</xref>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 364 367 364 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Bertolotti1">[8]</xref>
###xml 475 478 475 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-May1">[9]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Ohno1">[10]</xref>
###xml 691 695 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Li1">[11]</xref>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Azuma1">[12]</xref>
The EWS gene was first cloned from the Ewing's sarcoma chromosomal breakpoint, where the translocation generates a fusion between EWS and an ETS-family transcription factor gene, FLI-1[7]. EWS encodes a putative RNA binding protein, which together with TLS/FUS and TAFII68/TAF15 form the TET family of proteins with presumptive roles in transcription and splicing [8]. The NTD of EWS mediates potent transcriptional activation when fused to a heterologous DNA binding domain [9], while its C-terminal domain, which is lost in the translocation gene product, is involved in RNA recognition [10]. Recently, EWS was shown to be essential for meiosis, B-cell development and cellular senescence [11], as well as in mitosis [12].
###end p 10
###begin p 11
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Rivera1">[13]</xref>
###xml 157 160 157 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lee1">[14]</xref>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Reddy1">[15]</xref>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Haber1">[16]</xref>
###xml 622 626 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Rauscher1">[17]</xref>
###xml 683 686 683 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 789 792 789 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 806 809 806 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Ladanyi1">[6]</xref>
###xml 824 831 824 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS/WT1</italic>
###xml 944 948 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim1">[18]</xref>
###xml 1104 1108 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim2">[19]</xref>
The Wilms tumor suppressor gene WT1 encodes a Kruppel-like transcription factor which is mutated in a subset of Wilms tumor, a childhood kidney cancer [13]. WT1 encodes four Cys2His2 zinc-fingers in the C-terminus that mediate sequence specific DNA binding and the NTD containing both transcriptional activation and repression domains [14], [15]. WT1 is subjected to two alternative splicing events, one of which involves the inclusion or exclusion of three amino acids, lysine, threonine and serine (KTS), between the zinc-fingers 3 and 4 [16]. The KTS insertion leads to a markedly decreased DNA binding affinity of WT1 [17]. In nearly all cases of DSRCT, only the last 3 exons of WT1 encoding the last three zinc fingers are fused to the NTD of EWS, and the alternative KTS splicing of WT1 is preserved [6]. As a result, EWS/WT1 produces two isoforms: EWS/WT1(-KTS) and EWS/WT1(+KTS) that differs in the DNA binding affinity and specificity [18]. It was subsequently shown that only the EWS/WT1(-KTS) isoform, but not the EWS/WT1(+KTS), possesses the transforming activity in NIH3T3 cell-based assays [19]. Therefore, most efforts have focused on the identification of transcriptional targets of the EWS/WT1(-KTS) isoform.
###end p 11
###begin p 12
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gerald3">[4]</xref>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDGF-A</italic>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lee2">[20]</xref>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFR1</italic>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Finkeltov1">[21]</xref>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL2RB</italic>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Wong1">[22]</xref>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAIAP3</italic>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Palmer1">[23]</xref>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TALLA-</italic>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Ito1">[24]</xref>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC15</italic>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Reynolds1">[25]</xref>
To date, a small number of direct transcriptional targets of EWS/WT1(-KTS) have been identified (reviewed in [4]), which include PDGF-A (platelet-derived growth factor A) [20], IGFR1 (insulin-like growth-factor receptor 1) [21], IL2RB (interleukin 2 receptor beta) [22], BAIAP3 (BAI1-associated protein 3) [23], a potential regulator of growth-factor release, and TALLA-1 (T-cell acute lymphoblastic leukemia-associated antigen 1) [24], a gene encoding a tetraspanin-family protein. In contrast, there is only a single target gene identified for EWS/WT1(+KTS), which is LRRC15 (leucine-rich repeat containing 15) [25], a gene implicated in cell invasion. The native WT1(+/-KTS) isoforms do not regulate any of these transcripts, indicating that the loss of zinc finger 1 and/or the presence of EWS transactivation domain (NTD) may confer differential target gene specificity to EWS/WT1. Another interesting observation is that all of the identified target genes are regulated specifically by either the EWS/WT1(-KTS) or the (+KTS), but not both, clearly demonstrating the differential target gene specificity of the two isoforms.
###end p 12
###begin p 13
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Barnes1">[26]</xref>
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Xia1">[27]</xref>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMAT</italic>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Engel1">[28]</xref>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
ENT4 (equilibrative nucleoside transporter 4) is a member of the equilibrative nucleoside transporter (ENT) family (SLC29) and has recently been shown to be a pH-dependent adenosine transporter [26], [27]. Interestingly, ENT4 also accepts a number of biogenic amines as substrates and was alternatively named plasma membrane monoamine transporter (PMAT) [28]. In this study, we demonstrate that ENT4 is transcriptionally activated by both isoforms of EWS/WT1 and is highly expressed in DSRCT, implicating ENT4 as a potential therapeutic target.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Identification of ENT4 as a target gene of EWS/WT1(-KTS) and EWS/WT1(+KTS)
###end title 15
###begin p 16
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Palmer1">[23]</xref>
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gerald3">[4]</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Wong1">[22]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Palmer1">[23]</xref>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMAT</italic>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Engel1">[28]</xref>
###xml 736 740 736 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Baldwin1">[29]</xref>
###xml 937 941 937 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1064 1068 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1081 1088 1081 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1B</xref>
###xml 1175 1179 1175 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1230 1234 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1290 1294 1290 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1401 1405 1401 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1531 1538 1531 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1B</xref>
###xml 1576 1580 1576 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1835 1842 1835 1842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002353.s001">Fig. S1</xref>
###xml 1960 1964 1960 1964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 2013 2017 2013 2017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 2062 2066 2062 2066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
To identify the direct target genes of EWS/WT1(-KTS), we have previously performed expression profiling analysis with an inducible cell line expressing EWS/WT1(-KTS) [23]. This approach identified a number of EWS/WT1(-KTS) target genes which include several known genes and ESTs [4], [22], [23]. In the present study, we further characterized one of the EST transcripts (GenBank accession # R13346) which was induced by EWS/WT1(-KTS) expression with variable magnitudes in duplicate microarray experiments (21.0- and 3.1-fold induction). Sequence analysis revealed that the EST belongs to a recently identified novel monoamine transporter, PMAT[28], and independently identified as a new member of equilibrative nucleoside transporter, ENT4, with high-affinity for adenosine [29]. To validate this finding, we generated an independent tetracycline (Tet)-repressible EWS/WT1(-KTS) expressing cell line, UF5. A quantitative measurement of ENT4 transcripts following the induction of EWS/WT1(-KTS) for 12 hrs in UF5 cells demonstrated a 4-fold increase in endogenous ENT4 expression (Fig. 1B). The presence or absence of Tet in the control UV9 cells did not affect the level of ENT4 expression. To determine whether the induction of ENT4 was specific to the EWS/WT1(-KTS) isoform, we examined ENT4 expression in UED5 cells expressing EWS/WT1(+KTS). Surprisingly, we observed a robust 7-fold induction of ENT4 following the expression of EWS/WT1(+KTS), which is higher than the 4-fold induction observed with EWS/WT1(-KTS) expression (Fig. 1B). The difference in the magnitude of ENT4 induction was not due to the difference in the expression levels of the two EWS/WT1 isoforms, since the -KTS was expressed at a higher level in UF5 cells than the +KTS in UED5 cells as demonstrated by SYBR Green quantitative RT-PCR (qRT-PCR) (Supplement Fig. S1). In addition, an inducible expression of native WT1, either the -KTS or +KTS, did not alter the level of endogenous ENT4 expression (data not shown), demonstrating that ENT4 is specifically activated by EWS/WT1. Thus, ENT4 represents the first target gene which is transcriptionally activated by both isoforms of EWS/WT1.
###end p 16
###begin title 17
Identification of ENT4 as a target of EWS/WT1 in DSRCT.
###end title 17
###begin p 18
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 551 555 551 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 741 745 741 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 966 970 966 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 975 980 975 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1049 1053 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1079 1083 1079 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1108 1113 1108 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1195 1202 1195 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1220 1224 1220 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1293 1297 1293 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1310 1314 1310 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 808 813 <span type="species:ncbi:9606">human</span>
###xml 918 923 <span type="species:ncbi:9606">human</span>
A. Schematic representation of EWS/WT1 chimeric protein. The activation domain of EWS and the three zinc fingers of WT1 (DNA biding domain) are indicated. KTS indicates the alternative KTS splicing. B. Induction of ENT4 expression by both isoforms of EWS/WT1. Total RNA isolated from cells with Tet-repressible expression of EWS/WT1(-KTS) (UF-5), EWS/WT1(+KTS) (UED5) and empty vector (UV9) grown in the presence or absence of Tet for 12 hrs was analyzed by qRT-PCR using ENT4 TaqMan probe (Applied Biosystems). Fold induction represents the level of ENT4 expression following the inducible expression of EWS/WT1 (-Tet) relative to the uninduced (+Tet). Data were analyzed by comparative Ct method using GAPDH as a control. C. Expression of ENT4 in primary DSRCT and Ewing's sarcoma specimens, and in normal human tissues. Total RNAs isolated from primary tumors of DSRCT and Ewing's sarcoma specimens and from normal human brain, heart and spleen were analyzed for ENT4 and GAPDH expression using TaqMan quantitative RT-PCR. Relative expression of ENT4 is shown as the ratio of ENT4 transcripts relative to GAPDH transcripts (note the scale difference in the left and the right panels). D. RNA in situ hybridization of ENT4 in DSRCT. Two frozen DSRCT samples were sectioned and hybridized to ENT4 riboprobes. ENT4 expression is restricted to tumor cells (antisense probe). No staining was observed with a control (sense) probe. Tumor sections were also stained with hemotoxylin and eosin (H&E).
###end p 18
###begin title 19
Tumor-specific expression of ENT4 in DSRCT
###end title 19
###begin p 20
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 381 400 381 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1C, left panel</xref>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Barnes1">[26]</xref>
###xml 491 511 491 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1C, right panel</xref>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 700 707 700 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-situ</italic>
###xml 775 779 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 856 863 856 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1D</xref>
###xml 895 899 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 209 214 <span type="species:ncbi:9606">human</span>
To establish ENT4 as a physiological target of EWS/WT1, we next examined the expression of ENT4 in primary DSRCT samples. Total RNAs from four DSRCT and three Ewing's sarcoma tumor specimens as well as normal human tissues were isolated and analyzed for ENT4 expression by qRT-PCR. All four DSRCT specimens showed higher expression of ENT4 than any of the Ewing's sarcoma samples (Fig. 1C, left panel) or the two tissues (brain and heart) where ENT4 is reported to be highly expressed [26] (Fig. 1C, right panel). In fact, compared to the Ewing's sarcoma case (#6052) with the highest ENT4 expression, DSRCT samples expressed at least 2- to 20-fold higher level of ENT4 transcripts. Importantly, RNA in-situ analysis with two cases of DSRCT clearly revealed a tumor-specific ENT4 expression with little or no expression in the surrounding stromal tissues (Fig. 1D). These results establish that ENT4 is a physiological target of EWS/WT1 and is highly expressed by the tumor cells of DSRCT.
###end p 20
###begin title 21
ENT4 promoter is transactivated by both isoforms of EWS/WT1
###end title 21
###begin p 22
###xml 122 126 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 188 192 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 243 250 241 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2A</xref>
###xml 472 476 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 504 511 502 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2C</xref>
###xml 552 559 550 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1B</xref>
###xml 621 625 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 759 763 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
We next wished to determine whether EWS/WT1(+/-KTS) isoforms can directly and independently transactivate the promoter of ENT4. We amplified approximately 2-kb proximal promoter region of ENT4, including the first exon containing the 5' UTR, (Fig. 2A) and inserted it into a promoterless pGL3-Basic luciferase plasmid (P1). Co-transfection of either EWS/WT1(-KTS) or EWS/WT1(+KTS) with the 2-kb promoter construct P1 resulted in a marked transcriptional activation of the ENT4 promoter by both isoforms (Fig. 2C). Consistent with our previous results (Fig. 1B), EWS/WT1(+KTS) expression led to a higher activation of the ENT4 promoter (10-fold) than EWS/WT1(-KTS) (6-fold). These results suggest that two isoforms can directly and independently transactivate ENT4 expression.
###end p 22
###begin title 23
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 70 75 <span type="species:ncbi:9606">human</span>
Identification of EWS-WT1(+KTS) and (-KTS) responsive elements in the human ENT4 promoter.
###end title 23
###begin p 24
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 442 446 442 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1287 1308 1273 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
A. Schematic representation of ENT4 gene. The dark grey box indicated by +1 represents the first non-coding exon and the transcription start site (+1). The second dark grey box marked by ATG represents exon 2 containing the starting ATG. The light grey box represents the GA-repeat sequence. The black box represents the GC-rich sequence. B. Schematics showing the luciferase reporter constructs (P1-P4) containing different fragments of the ENT4 promoter. P3 promoter construct contains the deletion of GA-repeat sequences (-915 to +272). The numbers are relative to the transcription start (+1). C. Direct transcriptional activation of ENT4 promoters by EWS/WT1. U2OS cells were co-transfected with either pcDNA3-EWS/WT1 (- or +KTS; 0.5 microg) or with pcDNA3 along with the promoter-reporter constructs (P1, P2, P3 or P4; 0.5 microg) and Renilla luciferase (0.1 microg) using FuGENE 6. Luciferase activity was measured at 48 hrs post-transfection and expressed as relative luciferase activity compared to the empty vector. Data represent the mean+/-S.D. from three independent experiments. D. Schematics showing the three putative EWS/WT1(-KTS) binding sites (black boxes) within the GC-rich region of the P2 promoter and the mutated derivatives, M1, M2, M3 and M2/M3 constructs (see Materials and Methods for detail). E. Identification of the EWS/WT1(-KTS) responsive element M2. Luciferase-reporter assay was performed as in (C) except with the promoter-reporter constructs shown in (D). Data represent the mean+/-S.D. from three independent experiments.
###end p 24
###begin title 25
Identification of the -KTS and +KTS specific responsive elements in ENT4 promoter
###end title 25
###begin p 26
###xml 67 82 67 82 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GXGGXGGXG-3&#8242;</named-content>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim1">[18]</xref>
###xml 110 137 110 137 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-(G/C)(C/G)(G/C)TGGGGG-3&#8242;</named-content>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Wong1">[22]</xref>
###xml 261 277 261 277 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAGG(A/G)-3&#8242;</named-content>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Reynolds1">[25]</xref>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 622 629 622 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2A</xref>
###xml 684 687 684 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 760 767 760 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2B</xref>
###xml 1027 1034 1027 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2C</xref>
###xml 1181 1185 1181 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1752 1756 1752 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 2007 2010 2007 2010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 1746 1751 <span type="species:ncbi:9606">human</span>
EWS/WT1(-KTS) has been shown to bind to either a GC-rich sequence (5'-GXGGXGGXG-3') [18] or a E-WRE sequence (5'-(G/C)(C/G)(G/C)TGGGGG-3') [22]. On the other hand, EWS/WT1(+KTS) binds to a novel recognition sequence termed, E(KTS)RE, which has been defined as (5'-GGAGG(A/G)-3') [25]. Inspection of the 2-kb human ENT4 promoter sequences revealed three potential EWS/WT1(-KTS) responsive elements (GC-rich) located downstream of the transcriptional start site and a 760-bp stretch of GA-repeats, which contains more than 50 potential +KTS binding sites, E(KTS)RE motif, located upstream of the transcriptional start site (Fig. 2A). To test whether these sequences can function as the cis-regulatory elements, we generated various promoter deletion constructs (Fig. 2B). A deletion of 1700-bp region (-1450 to +270) upstream of the GC-rich sequences (promoter P2), which includes the GA-repeat sequences containing more than 50 potential E(KTS)RE elements, resulted in a complete loss of EWS/WT1(+KTS)-mediated transactivation (Fig. 2C). A smaller deletion encompassing mostly the GA-repeat sequences (promoter P3) also completely abrogated the +KTS-mediated transactivation of the ENT4 promoter, demonstrating that the multiple E(KTS)RE sites in the GA-repeat sequences likely function as the EWS/WT1(+KTS) response element. In contrast, the P2 promoter (330-bp) containing mostly the GC-rich sequences was highly activated (21-fold) by EWS/WT1(-KTS), indicating that the GC-rich sequences likely mediate the transactivation by the -KTS isoform. EWS/WT1(-KTS) activated the P3 promoter to a similar level (5-fold) as the 2-kb P1 promoter (6-fold), indicating that the removal of negative elements in the 5' upstream region (-1450 to -915) of the human ENT4 promoter may be responsible for the augmented activation of the P2 promoter by EWS/WT1(-KTS). Deletion of the GC-rich sequences (P4) resulted in a reduced but not complete absence of transactivation by the -KTS, suggesting the presence of additional cis-elements for EWS/WT1(-KTS). Interestingly, removal of the GC-rich sequences (P4) also led to a reduction in the EWS/WT1(+KTS)-mediated transactivation, demonstrating that the GC-rich sequences are needed to achieve full transactivation by EWS/WT1(+KTS).
###end p 26
###begin p 27
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 208 215 208 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2D</xref>
###xml 280 285 280 285 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGGGG</underline>
###xml 296 301 296 301 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AAAAA</underline>
###xml 380 387 380 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2E</xref>
###xml 472 477 472 477 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGGGG</underline>
###xml 465 480 465 480 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCGG<underline>GGGGG</underline>-3&#8242;</named-content>
###xml 491 496 491 496 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AAAAA</underline>
###xml 484 499 484 499 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCGG<underline>AAAAA</underline>-3&#8242;</named-content>
###xml 640 645 640 645 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGGGG</underline>
###xml 659 664 659 664 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AAAAA</underline>
###xml 635 669 635 669 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CT<underline>GGGGG</underline>CG-3&#8242; to 5&#8242;-CT<underline>AAAAA</underline>CG-3&#8242;</named-content>
###xml 976 983 976 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2E</xref>
###xml 1062 1065 1062 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1307 1314 1307 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2E</xref>
To precisely define the -KTS-specific response elements in the GC-rich region of the ENT4 promoter, we introduced base substitutions within the three potential EWS/WT1(-KTS) binding sites of the P2 promoter (Fig. 2D). Mutation of the first potential binding site M1 at +370 (5'-GAGGGGGTC-3' to GAAAAAATC-3') had no effect on the EWS/WT1(-KTS)-mediated activation of the promoter (Fig. 2E). However, mutation of the second binding site M2 at +440 (antisense strand: 5'-GCGGGGGGG-3' to 5'-GCGGAAAAA-3') resulted in approximately 60% reduction in the activation of the P2 promoter by the -KTS isoform. Altering the third site M3 at +570 (5'-CTGGGGGCG-3' to 5'-CTAAAAACG-3') showed a slight decrease in the EWS/WT1(-KTS)-mediated transactivation, but it was not statistically significant. Consistent with this, mutations at both the M2 and M3 sites (the M2/M3 promoter) in the GC-rich region displayed a similar level of reduction in the reporter assay as the single M2 mutation (Fig. 2E), demonstrating that the M2, but not the M1 or the M3 sites, functions as the cis-regulatory element for EWS/WT1(-KTS). These observations also indicate the existence of other EWS/WT1(-KTS) responsive element(s) within the GC-rich region. EWS/WT1(+KTS) had no discernible activity on any of the base substituted promoters (Fig. 2E). We did not attempt to define the +KTS responsive element in the GA-repeat sequences due to the presence of more than 50 potential E(KTS)RE sites.
###end p 27
###begin title 28
EWS/WT1 is recruited to ENT4 promoter in vivo
###end title 28
###begin p 29
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 740 747 740 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3B</xref>
###xml 848 852 848 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1044 1062 1044 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3B, UF5 panel</xref>
###xml 1111 1118 1111 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1179 1183 1179 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1194 1213 1194 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3B, UED5 panel</xref>
###xml 1276 1280 1276 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
We next performed chromatin immunoprecipitation (ChIP) assay to determine whether EWS/WT1 is recruited to the ENT4 promoter in vivo. UF5 and UED5 cells were induced to express EWS/WT1(-KTS) and EWS/WT1(+KTS), respectively, and formaldehyde-crosslinked DNA was immunoprecipitated using an antibody that recognizes the C-terminal domain of WT1 (C-19) to enrich for the chromatin bound by EWS/WT1. The endogenous WT1 is not detectable in U2OS cells by western blotting (data not shown), and thus, the C-19 antibody should be specific for EWS/WT1. We designed primers flanking the GC-rich sequences to examine the EWS/WT1(-KTS) binding and a primer set near the 5' region of the GA-repeat sequences for detecting the EWS/WT1(+KTS) recruitment (Fig. 3B). ChIP analysis of UF5 cells demonstrated that EWS/WT1(-KTS) was present near the GC-rich region of ENT4 promoter as shown by the specific amplification of the GC-rich sequences with the chromatin immunoprecipitated with C-19 antibodies but not with the IgG-immunoprecipitated chromatin control (Fig. 3B, UF5 panel). Similarly, ChIP analysis of UED5 cells showed in vivo recruitment of EWS/WT1(+KTS) to the GA-repeat region of the ENT4 promoter (Fig. 3B, UED5 panel). Recruitment of the EWS/WT1 isoforms to these regions of the ENT4 promoter was specific since the control primers amplifying the regions either 1kb upstream from the GA-repeat region (CONT1) or 1kb downstream from the GC-rich region (CONT2) failed to amplify any product.
###end p 29
###begin title 30
###xml 7 14 7 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 49 53 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
Direct in vivo recruitment of EWS/WT1(+/-KTS) to ENT4 promoter.
###end title 30
###begin p 31
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 868 872 868 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 929 933 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 713 719 <span type="species:ncbi:9986">rabbit</span>
###xml 862 867 <span type="species:ncbi:9606">human</span>
A. Western blot analysis of EWS/WT1 in the inducible cell lines (UF5 and UED5) and in the primary DSRCT cell line (JN-DSRCT-1), probed with anti-EWS antibody (upper panel) or with anti-WT1 antibody (lower panel, C-19, Santa Cruz). EWS/WT1 expression was induced (-Tet) for about 14 hrs in UF5 and UED5 cells. B. Chromatin immunoprecipitation (ChIP) analysis. Schematics of ENT4 promoter and the locations of the primers (arrows) used to amplify the GA-repeat and the GC-rich regions are shown. EWS/WT1(+KTS) or (-KTS) expression was induced for 14 hrs in UED5 and UF5 cells, respectively, and crosslinked with 1% formaldehyde. Crosslinked chromatin immunoprecipitated with anti-WT1 antibody (C-19, Santa Cruz) or rabbit IgG control was used in PCR amplification with either primers in the GA-repeat (for UED5 cells) or the GC-rich (for UF5 cells) regions of the human ENT4 promoter. Primers amplifying the control regions of the ENT4 promoter (CONT1 and CONT2) and GAPDH promoter were used as negative controls. C. ChIP analysis in JN-DSRCT-1 cells. Formaldehyde-crosslinked chromatin from JN-DSRCT-1 cells was examined by ChIP analysis using the same primer sets as in (B).
###end p 31
###begin p 32
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Nishio1">[30]</xref>
###xml 249 252 249 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 427 434 427 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3A</xref>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 796 799 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 816 820 816 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1042 1049 1042 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3C</xref>
###xml 1290 1294 1290 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1365 1372 1365 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2C</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">3B</xref>
###xml 1444 1447 1444 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1475 1479 1475 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1646 1659 1646 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3B and C</xref>
###xml 1890 1902 1890 1902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4 in vivo</italic>
A DSRCT cell line, JN-DSRCT-1, is the only established cell line derived from a primary DSRCT specimen and naturally expresses both isoforms of EWS/WT1 [30]. The breakpoint of EWS/WT1 translocation in JN-DSRCT-1 cell line is different (intron 10 of EWS) from the prototypical EWS/WT1 translocation (intron 7 of EWS) expressed in UF5 and UED5 cells. Thus, JN-DSRCT-1 cells express slightly slower migrating isoforms of EWS/WT1 (Fig. 3A). Immunoblot analysis with the C-19 antibody further revealed that JN-DSRCT-1 cells do not express detectable levels of endogenous WT1. To determine whether naturally occurring EWS/WT1 is recruited to the ENT4 promoter, we performed the ChIP analysis in JN-DSRCT-1 cells. Consistent with our previous ChIP results, EWS/WT1 was physically recruited near the two cis-elements in the ENT4 promoter in JN-DSRCT-1 cells as demonstrated by specific PCR amplifications of both the GA-repeat and the GC-rich regions of the promoter with chromatin immunoprecipitated with antibodies to WT1 (C-19), but not with IgG (Fig. 3C). As expected, the control primers (CONT1, CONT2 and GAPDH) did not yield any PCR products. Since the antibody (C-19) recognizes both isoforms of EWS/WT1, we cannot demonstrate the recruitment of each isoform to the specific regions of the ENT4 promoter in JN-DSRCT-1 cells. However, based on our previous results (Fig. 2C and 3B), it is likely that each isoform is recruited to the respective cis-regulatory elements of the ENT4 promoter in JN-DSRCT-1 cells. Interestingly, we consistently observed a more robust amplification of the GA-repeat region than the GC-rich region in our ChIP assays (Fig. 3B and C), which may indicate the presence of more EWS/WT1 in the GA-repeat region (which contains more than 50 EWS/WT1(+KTS) binding sites). Together, these results demonstrate that EWS/WT1 is recruited to the proximal promoter region of ENT4 in vivo.
###end p 32
###begin title 33
ENT4 is highly and specifically expressed in JN-DSRCT cell line
###end title 33
###begin p 34
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 412 419 412 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g004">Fig. 4A</xref>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT1-3</italic>
###xml 541 545 541 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 678 696 678 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002353.s002">Supplement Fig. S2</xref>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 850 854 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 877 890 877 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1C and D</xref>
###xml 622 627 <span type="species:ncbi:9606">human</span>
We next sought to determine the expression level of ENT4 in JN-DSRCT-1 cells. For comparison, we used two Ewing's sarcoma cell lines A4573 and CHP100, both of which express the EWS/FLI-1 translocation gene product. A quantitative measurement of the transcripts by qRT-PCR revealed that expression of ENT4 was about 15- to 30-fold higher in JN-DSRCT-1 cells when compared to A4573 and CHP100 cells, respectively (Fig. 4A). Expression of other equilibrative nucleoside transporters (ENT1-3) was not enriched in JN-DSRCT-1 cells. Expression of ENT4 was also at least 50-fold or higher in JN-DSRCT-1 cells than in three other human cancer cell lines examined, PC3, DU-145 and U2OS (Supplement Fig. S2). These results clearly demonstrate that ENT4 is highly and specifically enriched in JN-DSRCT-1 cells, consistent with the highly abundant expression of ENT4 in the primary DSRCT (Fig. 1C and D).
###end p 34
###begin title 35
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
ENT4 transcript is highly abundant in JN-DSRCT-1 cells and is regulated by EWS/WT1.
###end title 35
###begin p 36
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT</italic>
###xml 186 189 186 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT1</italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT2</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT3</italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT1</italic>
###xml 964 968 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
A. Quantitative measurement of ENT-family transcripts. Total RNA isolated from JN-DSRCT-1 and two Ewing's sarcoma cells (A4537 and CHP100) was analyzed for relative transcript levels of ENT-family genes using Taqman probes for ENT1, ENT2, ENT3, and ENT4. ENT1 transcript level from A4573 cells was arbitrarily set to 1 and used as a reference for quantification of other ENT-family transcripts in A4573 and other cells. Data were analyzed by comparative Ct method using GAPDH as a control. Data represent the mean+/-S.D. from three independent experiments. B. siRNA knockdown of EWS/WT1. JN-DSRCT-1 cells were transfected with either control, WT1-1 or WT1-2 siRNAs using Lipofectaminetrade mark 2000, and at 48 hrs post-transfection, total cell lysates were analyzed by western blotting using anti-EWS, anti-WT1 and anti-actin (loading control) antibodies. C. Total RNA was isolated from the siRNA-transfected cells (as described in B) and the expression level of ENT4 was determined by qRT-PCR as in (A). Data represent the mean+/-S.D. from three independent experiments.
###end p 36
###begin p 37
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 194 201 194 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g004">Fig. 4B</xref>
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 488 495 488 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g004">Fig. 4C</xref>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
To further demonstrate that EWS/WT1 is directly regulating the ENT4 expression, we used a small interfering RNA (siRNA) approach to deplete the level of EWS/WT1 in JN-DSRCT-1 cells. As shown in Fig. 4B, transfection of two different siRNAs directed against the 3' UTR of WT1 resulted in a marked reduction in the level of EWS/WT1 as compared to the control siRNA. Depletion of EWS/WT1 by two independent WT1-siRNAs concomitantly led to approximately 60% decrease in the ENT4 transcripts (Fig. 4C), further supporting the direct transcriptional regulation of ENT4 by EWS/WT1.
###end p 37
###begin title 38
Adenosine analog 2-CdA displays increased cytotoxicity in JN-DSRCT cells
###end title 38
###begin p 39
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Elwi1">[31]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Spratlin1">[32]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Baldwin1">[29]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Engel1">[28]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Barnes1">[26]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Xia1">[27]</xref>
###xml 1104 1108 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kushner1">[33]</xref>
###xml 1370 1377 1363 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g005">Fig. 5A</xref>
###xml 1509 1516 1498 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g005">Fig. 5A</xref>
###xml 2012 2019 1985 1992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g005">Fig. 5A</xref>
###xml 1095 1103 <span type="species:ncbi:9606">patients</span>
Nucleoside transporters are thought to be important for the efficacy of nucleoside analogs used in chemotherapy such as gemcitabine, a pyrimidine nucleoside analog [31], [32]. Despite the initial classification of ENT4 as an adenosine transporter and a new member of equilibrative nucleoside transporter [29], ENT4 was shown to be a poor transporter of adenosine at neutral pH [28]. Recently, however, it was demonstrated that ENT4 exhibits a maximum adenosine transporter activity at pH 6.0 to 6.6 and is primarily localized at the plasma membrane [26], [27]. To examine whether we can exploit the high level of ENT4 expression and its adenosine transporter activity in DSRCT, we treated JN-DSRCT-1 and the control cells, A4573 and CHP100, with various nucleoside analogs: 2-chloro-2'-deoxyadenosine (2-CdA, also known as cladribine), 2-fluoroadenine-9-beta-D-arabinofuranoside (F-ara-A, also known as fludarabine), or 5-fluorouracil (5-FU) as a pyrimidine analog control. For comparison, we also treated cells with doxorubicin, a highly cytotoxic chemotherapeutic compound used to treat DSRCT patients [33]. When cells were cultured at pH 6.6 and treated with a low dose (0.1 microM) of 2-CdA, JN-DSRCT-1 cells displayed a modest but significant increase in sensitivity to 2-CdA while the control A4573 and CHP100 cells remained fully viable under the same condition (Fig. 5A). Under the standard culture condition (pH 7.4), the same dose of 2-CdA (0.1 microM) had no cytotoxic effects on JN-DSRCT-1 cells (Fig. 5A). A higher dose of 2-CdA (1 microM) at pH 6.6 also led to a significant increase in cytotoxicity in JN-DSRCT-1 cells as compared to the control cells. At the highest dosage (10 microM), 2-CdA was highly cytotoxic to all cells examined. In contrast, different doses up to 1 microM of F-ara-A under pH 6.6 were not cytotoxic to any of the cell lines tested. However, 10 microM of F-ara-A at pH 6.6 resulted in a dramatic increase in cytotoxicity in JN-DSRCT-1 cells compared to the control cells (Fig. 5A). The same dose of F-ara-A (10 microM) at neutral pH 7.4 had only a marginal effect on JN-DSRCT-1 cell viability (see pH 7.4 panel). Increasing doses of 5-FU showed minimal cytotoxicity in all cells cultured at either pH conditions. Doxorubicin treatment at pH 6.6 resulted in a similar dose-dependent cytotoxicity as that observed under the neutral pH.
###end p 39
###begin title 40
JN-DSRCT-1 cells display dose- and pH-dependent cytotoxicity to adenosine analogs.
###end title 40
###begin p 41
###xml 371 372 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 799 806 776 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g004">Fig. 4C</xref>
###xml 869 890 846 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 992 993 967 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
A. Cytotoxic assay. JN-DSRCT-1, A4573, and CHP100 cells were exposed to various concentrations (0.01-10 microM) of 2-CdA, F-ara-A, 5-FU or doxorubicin (Dox) for 72 hrs at pH 7.4 or pH 6.6. Cell viability was determined with Cell Counting Kit-8 (Dojindo Molecular Technologies). Data represent the mean+/-S.D. from three independent experiments performed in duplicate. *, p value < 0.01 was calculated by first performing one-way ANOVA analysis followed by Tukey's multiple comparison test. B and C. JN-DSRCT-1 cells were transfected with either control, WT1-1 or WT1-2 siRNAs using Lipofectaminetrade mark 2000 for 24 hrs, and the cells were treated with either 1 microM of 2-CdA (B) or 10 microM of F-ara-A (C) at pH 6.6 for 48 hrs. The knockdown efficiency of ENT4 was confirmed by qRT-PCR (as in Fig. 4C) and cytotoxicity was assessed by Toxilight BioAssay Kit (see Materials and Methods). Data represent the mean+/-S.D. from at least three independent experiments performed in duplicate. p value was calculated by first performing one-way ANOVA analysis followed by Tukey's multiple comparison test.
###end p 41
###begin p 42
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 373 380 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g005">Fig. 5B</xref>
###xml 651 658 639 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g005">Fig. 5C</xref>
To examine whether reducing the ENT4 transcript level by WT1-siRNA could decrease the cytotoxicity of 2-CdA and F-ara-A, JN-DSRCT-1 cells were transfected with control or WT1-siRNAs, followed by treatment with 1 microM of 2-CdA or 10 microM of F-ara-A at pH 6.6. Decreasing the level of ENT4 with WT1-2 siRNA resulted in a markedly reduced cytotoxicity to 2-CdA treatment (Fig. 5B). WT1-1 siRNA transfected cells also showed slightly reduced cytotoxicity to 2-CdA, but it did not reach statistical significance. By contrast, transfection of either WT1 siRNAs resulted in a significant reduction in F-ara-A (10 microM) mediated cytotoxicity at pH 6.6 (Fig. 5C). Collectively, these results are consistent with the cytotoxic effects of 2-CdA and F-ara-A being mediated, at least in part, through ENT4 in JN-DSRCT-1 cells.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim1">[18]</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Morrison1">[34]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Bor1">[35]</xref>
###xml 759 763 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim2">[19]</xref>
###xml 796 804 796 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1018 1025 1018 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
DSRCT-specific EWS/WT1 translocation results in the production of two fusion proteins with distinct biological activities, which has not been observed in other EWS-related chromosomal translocations. Two EWS/WT1 isoforms possess different DNA binding specificity due to the alternative KTS splicing event [18]. In addition, EWS/WT1(+KTS) could potentially have a non-transcriptional role since WT1(+KTS) isoform has recently been demonstrated to bind to cellular mRNA [34] and participate in the control of translation [35]. Thus, the existence of two isoforms of EWS/WT1 in DSRCT raises the following interesting questions: what are the roles of each isoforms and are they both required for tumorigenesis? The latter question has been addressed by Kim et al [19] who demonstrated that, at least in vitro, only the EWS/WT1(-KTS) isoform possesses the transforming activity using the NIH3T3 cell-based transformation assays. However, it remains to be determined whether the -KTS isoform is sufficient for tumorigenesis in vivo.
###end p 44
###begin p 45
###xml 153 161 153 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lee2">[20]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Ito1">[24]</xref>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC15</italic>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Reynolds1">[25]</xref>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
To address the oncogenic role of EWS/WT1, most of the efforts have been focused on identifying the transcriptional target of the -KTS isoform due to its in vitro transforming property. Because of altered DNA binding properties of the -KTS and the +KTS isoforms, it is presumed that their target genes would be different. Consistent with this notion, nearly all of the EWS/WT1 target genes identified are transcriptionally regulated only by the EWS/WT1(-KTS) isoform [20]-[24]. In contrast, LRRC15 is the only EWS/WT1(+KTS) target gene identified to date and is solely regulated by the +KTS [25]. Therefore, it was quite surprising to find that ENT4 was transcriptionally activated by both isoforms of EWS/WT1.
###end p 45
###begin p 46
###xml 121 124 121 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 390 393 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 453 459 453 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2</xref>
###xml 488 491 488 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 744 748 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 876 880 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 965 969 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1003 1010 1003 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g001">Fig. 1B</xref>
###xml 1083 1090 1083 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g002">Fig. 2C</xref>
###xml 1218 1222 1218 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1233 1240 1233 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002353-g003">Fig. 3C</xref>
###xml 1420 1424 1420 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
The promoter analysis revealed that the transcriptional activation by two EWS/WT1 isoforms is mediated through different cis-regulatory elements within the ENT4 promoter. The GA-repeat sequences, which contain more than 50 potential binding sites for EWS/WT1(+KTS), mediate transactivation by the +KTS, whereas the GC-rich sequences containing the responsive element, M2, functioned as the cis-regulatory elements for the -KTS-specific transactivation (Fig. 2). The existence of distinct cis-regulatory elements for each EWS/WT1 isoforms raises an intriguing possibility of synergistic transcriptional activation by the two isoforms on the ENT4 promoter. However, coexpression of both isoforms did not result in a synergistic activation of the ENT4 promoter (data not shown). Our findings further suggest that EWS/WT1(+KTS) may play a more prominent role in the activation of ENT4 transcription than EWS/WT1(-KTS), based on the higher induction level of endogenous ENT4 transcripts by the +KTS isoform (Fig. 1B), higher transactivation by the +KTS in our promoter-reporter analysis (Fig. 2C), and by our ChIP analysis in which we observed a more robust amplification of the GA-repeat region than the GC-rich region of ENT4 promoter (Fig. 3C). A likely explanation for this is the presence of more than fifty EWS/WT1(+KTS) binding sites in the GA-repeat region. This may also help to explain the remarkably high level of ENT4 expression observed in both primary DSRCT specimens and JN-DSRCT-1 cell line, as well as the lack of synergy between the two isoforms in our promoter assay (the +KTS isoform may simply saturate the promoter). A highly abundant expression of ENT4 may be useful as an additional diagnostic marker of DSRCT although more cases need to be evaluated. Our study further suggests that it may be possible to identify additional target genes of EWS/WT1(+KTS) by examining the proximal promoter regions for the GA-repeat sequences.
###end p 46
###begin p 47
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Baldwin1">[29]</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Baldwin2">[36]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Barnes1">[26]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Engel1">[28]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Baldwin1">[29]</xref>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Barnes1">[26]</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Xia1">[27]</xref>
###xml 1137 1141 1137 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Gatenby1">[37]</xref>
###xml 1240 1244 1240 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Adair1">[38]</xref>
ENT4 is a member of the equilibrative nucleoside transporter (ENT) family (SLC29), which contains four isoforms [29]. ENT1 and ENT2 transport purine and pyrimidine nucleosides (e.g. uridine, adenosine, etc.) and their structural analogs. ENT3 is an intracellular nucleoside transporter, which may play a role in lysosomal transport of nucleosides [36]. ENT4 is unique in the ENT family as it is specific towards adenosine and adenosine analogs and does not significantly transport other nucleosides and their congeners [26], [28], [29]. The activity of ENT4 towards adenosine is low at pH 7.4, and recent reports have shown that ENT4 exhibits a maximum adenosine transport activity at pH 6.0 to 6.6 [26], [27]. The role of ENT4 in the genesis and progression of DSRCT is unknown, but it may have a role in supporting tumorigenesis by providing growth and survival advantages to the tumor cells in adapting to a tumor microenvironment. In general, the tumor microenvironement becomes hypoxic and acidic due to a limiting blood supply and increased acid production from the upregulation of glycolytic metabolic pathways by the tumor cells [37]. It has also been demonstrated that adenosine can stimulate angiogenesis under hypoxic conditions [38]. Thus, it is intriguing to speculate that DSRCT-specific expression of ENT4, a pH-dependent (acidic) adenosine transporter, might provide growth and survival advantages to the tumor cells (e.g. by stimulating angiogenesis) under hypoxic/acidic conditions, as well as increasing the nucleoside pool within the rapidly proliferating tumor cells.
###end p 47
###begin p 48
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kong1">[39]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kong1">[39]</xref>
###xml 596 604 596 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Hoffman1">[40]</xref>
###xml 805 809 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Galmarini1">[42]</xref>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
The expression level and pattern of the ENTs are an important determinant for the therapeutic efficacy of anticancer nucleoside analogs since many nucleoside analogs used in cancer chemotherapy depend on nucleoside transporters to enter tumor cells to exert their cytotoxicity (reviewed in [39]). For example, the expression of ENT1 in leukemia and certain solid tumors is related to the clinical efficacy of a number of nucleoside analogs such as cytarabine (Ara-C) and gemcitabine [39]. In light of this, our results demonstrating the cytotoxic effects of 2-CdA and F-ara-A in JN-DSRCT-1 cells in vitro are highly intriguing. Adenosine analogs such as 2-CdA and F-ara-A are an effective chemotherapeutic agent for the treatment of hairy cell leukemia and chronic lymphocytic leukemia, respectively [40]-[42]. However, efficacy of these adenosine analogs in solid tumors has not been reported. Our finding of ENT4 as a transcriptional target of EWS/WT1 highly expressed in DSRCT suggests that this transporter may represent an attractive pathway for targeting chemotherapeutic drugs into DSRCT.
###end p 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
Cell lines
###end title 50
###begin p 51
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lee2">[20]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Reynolds1">[25]</xref>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Lee2">[20]</xref>
###xml 464 468 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Nishio1">[30]</xref>
###xml 347 353 <span type="species:ncbi:9913">bovine</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
UF5, U2OS-derived cell line with tetracycline-repressible EWS/WT1(-KTS) expression, was generated as described previously [20]. UED5 cells with tetracycline-repressive EWS-WT1 (+KTS) expression [25] and UV9 control cells [20] were previously described. UV9, UF5 and UED5 were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 1 microg/ml tetracycline. A human DSRCT cell line, JN-DSRCT-1 (kindly provided by Dr. Nishio) [30] and Ewing's sarcoma cell lines, A4573 and CHP100 (kindly provided by Dr. Crystal Mackall, NCI), were maintained in 1:1 mixture of DMEM and Ham's F-12 with 10% FBS.
###end p 51
###begin title 52
Quantitative RT-PCR analysis
###end title 52
###begin p 53
###xml 439 443 439 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 733 738 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 791 795 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 837 841 837 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1044 1048 1044 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1132 1136 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1207 1212 1207 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1300 1307 1300 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS/WT1</italic>
###xml 1496 1523 1487 1514 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGGATCCTACAGCCAAGCTCC-3&#8242;</named-content>
###xml 1525 1554 1516 1545 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTGGTGTCTTTTGAGCTGGTCTG-3&#8242;</named-content>
###xml 1556 1561 1547 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 173 178 <span type="species:ncbi:9606">human</span>
###xml 1059 1064 <span type="species:ncbi:9606">human</span>
Total RNA was isolated from cell lines or tumor tissues with RNA STAT-60 (Tel-Test Inc. Friendswood, TX) according to the manufacturer's instruction. Total RNAs from normal human heart, brain and spleen were purchased from Zyagen (San Diego, CA). Two microgram of total RNA was treated with 1U of DNase I (Invitrogen, Carlsbad, CA) and reverse transcribed with SuperScript First-Strand Synthesis System (Invitrogen). For quantification of ENT4, equal amount of first-strand cDNA was mixed with each assay-on-demand TaqMan probes and Taqman Universal Master Mix (Applied Biosystems, Foster City, CA), and amplified using ABI prism 7700 sequence detection system (Applied Biosystems). Data were analyzed by comparative Ct method using GAPDH as an endogenous control. For the quantification of ENT4 in UV9, UF5 and UED5 cells, the level of ENT4 transcripts (normalized to GAPDH) in the absence of tetracycline was expressed as fold differences to the level of ENT4 in the presence of tetracycline (arbitrarily set to 1). For the quantification of ENT4 in normal human tissues, primary DSRCT and Ewing's sarcoma specimens, the ratio of ENT4 transcripts relative to the Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) transcripts was calculated using the comparative Ct method. For the quantification of EWS/WT1 expression in UF5 and UED5 cells, the relative expression was determined by using the Quantitecttrade mark SYBR Green PCR kit (Qiagen, Valencia, CA). The primers used for this assay were: 5'-TGGATCCTACAGCCAAGCTCC-3'; 5'-TTGGTGTCTTTTGAGCTGGTCTG-3'. GAPDH was used for standardization. All experiments were done in duplicate and data from minimum of three independent experiments were analyzed.
###end p 53
###begin title 54
ENT4 promoter constructs and luciferase reporter assays
###end title 54
###begin p 55
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 273 310 273 310 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GCGAGATCTGGTGGAAAGTGAAGGAAGGGCC 3&#8242;</named-content>
###xml 312 350 312 350 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CCGTTCGAACTCATCAGCCGCAAAGTTGGCTC 3&#8242;</named-content>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
A 2.0 kb fragment containing the human ENT4 promoter was obtained by PCR using human genomic DNA and inserted into the XhoI/Hind III sites of a promoterless firefly luciferase reporter pGL3-Basic plasmid (Promega, Madison, WI) to yield P1. The following primers were used: 5' GCGAGATCTGGTGGAAAGTGAAGGAAGGGCC 3'; 5' CCGTTCGAACTCATCAGCCGCAAAGTTGGCTC 3'. Three promoter-deletion constructs (P2, P3 and P4) were generated by digestion of P1 with restriction enzymes and ligation of promoter fragments. The mutant constructs (M1, M2, M3 and M2/M3) were generated using QuickChange Multi site-Directed Mutagenesis Kit (Stratagene, Cedar Creek, TX) using the following primers:
###end p 55
###begin p 56
###xml 11 50 11 50 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCCTCGCCATGGAAAAAATCGGCGCCACCGCC-3&#8242;</named-content>
###xml 62 101 62 101 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCGGTGGCGCCGATTTTTTCCATGGCGAGGGC-3&#8242;</named-content>
M1: sense, 5'-GCCCTCGCCATGGAAAAAATCGGCGCCACCGCC-3' antisense, 5'-GGCGGTGGCGCCGATTTTTTCCATGGCGAGGGC-3'
###end p 56
###begin p 57
###xml 11 54 11 54 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGAAGTTCCTCCCCGGATTTTTCCGCGCCACCCCATC-3&#8242;</named-content>
###xml 66 109 66 109 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATGGGGTGGCGCGGAAAAATCCGGGGAGGAACTTCG-3&#8242;</named-content>
M2: sense, 5'-CGAAGTTCCTCCCCGGATTTTTCCGCGCCACCCCATC-3' antisense, 5'-GATGGGGTGGCGCGGAAAAATCCGGGGAGGAACTTCG-3'
###end p 57
###begin p 58
###xml 11 55 11 55 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGGTCTGTCCTTTGCCTAAAAACGCAGGTCCGCGAGC-3&#8242;</named-content>
###xml 67 111 67 111 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTCGCGGACCTGCGTTTTTAGGCAAAGGACAGACCCC-3&#8242;</named-content>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
M3: sense, 5'-GGGGTCTGTCCTTTGCCTAAAAACGCAGGTCCGCGAGC-3' antisense, 5'-GCTCGCGGACCTGCGTTTTTAGGCAAAGGACAGACCCC-3'. The ENT4 promoter-reporter constructs (0.5 microg) were cotransfected into U2OS cells using FuGENE 6 (Roche, Indianapolis, IN), along with 0.5 microg pcDNA3-EWS/WT1(-KTS), -EWS/WT1(+KTS), or empty vector and renilla luciferase reporter plasmid (0.1 microg) for normalization of transfection variance. Luciferase activity was assayed at 48 hrs post-transfection using the Dual-Luciferase Reporter kit (Promega). Data were calculated from minimum of three experiments performed in duplicate.
###end p 58
###begin title 59
Chromatin immunoprecipitation (ChIP) analysis
###end title 59
###begin p 60
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Kim3">[43]</xref>
###xml 996 1000 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 1115 1142 1091 1118 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACCTGTCGGAGCCTTTGTCTG-3&#8242;</named-content>
###xml 1144 1171 1120 1147 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATCAGCCGCAAAGTTGGCTCG-3&#8242;</named-content>
###xml 1284 1310 1260 1286 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGCACAGCCCAGCTGGATGG-3&#8242;</named-content>
###xml 1312 1338 1288 1314 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCCATTCTCCTACTCAGTCC-3&#8242;</named-content>
###xml 1447 1473 1423 1449 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTAGTTGGAGCAATGGACTG-3&#8242;</named-content>
###xml 1475 1501 1451 1477 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTGGCATACAGCAGGAGCC-3&#8242;</named-content>
###xml 1613 1639 1577 1603 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGCAGTAGGCTTGGATGTGG-3&#8242;</named-content>
###xml 1641 1667 1605 1631 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AATGCTCCTCCTGCCACCTG-3&#8242;</named-content>
###xml 1801 1828 1753 1780 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTTACGGGCGCACGTAGCTCA-3&#8242;</named-content>
###xml 1830 1857 1782 1809 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CACCTTCCCCATGGTGTCTGA-3&#8242;</named-content>
###xml 573 579 <span type="species:ncbi:9986">rabbit</span>
###xml 643 649 <span type="species:ncbi:9986">rabbit</span>
ChIP analysis was performed as previously described [43] using ChIP assay kit (Upstate, Lake Placid, NY). After induction of EWS/WT1(-KTS) and EWS/WT1(+KTS) expression by removal of tetracycline, formaldehyde was added to a final concentration of 1% and cells were incubated at room temperature for 10 min. Cells were lysed in SDS lysis buffer (1% SDS, 50 mM Tris pH 8.0, 10 mM EDTA) and DNA was sheared by sonication to achieve an average length of approximately500-bp. Samples were diluted 10-fold in ChIP Dilution Buffer and incubated overnight at 4degreesC with either rabbit polyclonal anti-WT1 (C-19, Santa Cruz, Santa Cruz, CA) or with rabbit IgG. Samples were incubated with Salmon Sperm DNA/Protein A Agarose-50% Slurry and bound complexes were eluted in elution buffer (1% SDS, 0.1 M NaHCO3). Samples were incubated 4 hr at 65degreesC to reverse crosslinking and proteins were digested with Proteinase K. Following purification of DNA fragments (Qiaquick PCR purification kit, Qiagen), ENT4 promoter regions were amplified by PCR using primers (to detect EWS/WT1(-KTS) binding within the GC-rich region): 5'-ACCTGTCGGAGCCTTTGTCTG-3'; 5'-ATCAGCCGCAAAGTTGGCTCG-3', which yields a 452-bp product, and with primers (to detect EWS/WT1(+KTS) binding within the GA-repeat region): 5'-TGCACAGCCCAGCTGGATGG-3'; 5'-CCCATTCTCCTACTCAGTCC-3', which yields a 218-bp product. To control for specificity, the following primers were used: CONT1 primers: 5'-CTAGTTGGAGCAATGGACTG-3'; 5'-GCTGGCATACAGCAGGAGCC-3' (which amplify approximately1 kb upstream region of the GA-repeats, yielding a 250-bp product); CONT2 primers: 5'-CGCAGTAGGCTTGGATGTGG-3'; 5'-AATGCTCCTCCTGCCACCTG-3' (which amplify approximately1 kb downstream sequences of the GC-rich region, yielding a 400-bp product); and GAPDH promoter primers: 5'-TTTACGGGCGCACGTAGCTCA-3'; 5'-CACCTTCCCCATGGTGTCTGA-3', which yields a 462-bp product.
###end p 60
###begin title 61
RNA in situ analysis
###end title 61
###begin p 62
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Palmer1">[23]</xref>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 226 231 <span type="species:ncbi:9606">human</span>
RNA in situ hybridization was performed as described [23]. SP6 and T7 flanked PCR templates were used to generate digoxigenin-labeled riboprobes (Roche Molecular Biochemicals). The following ENT4 sequences were used as probe: human ENT4 (accession AK092242), nt 146-583 or nt 584-941. Primary DSRCT tumor samples were obtained from the Department of Pathology, Memorial Sloan Kettering Cancer Center. OTC-embedded samples were cut into 9 microm sections, fixed in 4% paraformaldehyde, digested with Proteinase K (4 microg/ml), treated with acetic anhydride, and dehydrated in increasing concentrations of ethanol. Sections were hybridized overnight with 1 ng/microl probe. Bound probe was detected using an alkaline phosphatase conjugated anti-digoxigenin antibody (Roche Molecular Biochemicals) followed by incubation with BM purple (Roche Molecular Biochemicals), an alkaline phosphatase substrate. Control sense riboprobes were tested for each tissue.
###end p 62
###begin title 63
siRNA knockdown analysis
###end title 63
###begin p 64
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT1</italic>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENT4</italic>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Li1">[11]</xref>
###xml 480 486 <span type="species:ncbi:9986">rabbit</span>
JN-DSRCT-1 cells were transfected with two small interfering RNA (siRNA) against the 3' UTR of WT1 (siWT1-1 and siWT2-2, purchased from Sigma-Aldrich, St. Louis, MO; siRNA ID: SASI_Hs01_00130271 and SASI_Hs01_00130272, respectively) or control scrambled siRNA. At 48 hrs post-transfection, total RNA was isolated, reverse-transcribed and quantified by RT-PCR using the Taqman probes against ENT4 as described above. The knockdown of EWS/WT1 was verified by western blotting using rabbit polyclonal anti-EWS (1:1000 dilution, [11]), anti-WT1 (C-19) (1:200 dilution, Santa Cruz Biotechnology) and anti-Actin (1:1000 dilution, Sigma-Aldrich) antibodies. All blots were visualized by Odyssey infrared system (LI-COR Bioscience, Lincoln, Nebraska).
###end p 64
###begin title 65
In vitro cytotoxicity assays
###end title 65
###begin p 66
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 924 928 917 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Liu1">[44]</xref>
###xml 1085 1086 1078 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1633 1637 1609 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002353-Miret1">[45]</xref>
###xml 1710 1717 1686 1693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Treated</sub>
###xml 1721 1730 1697 1706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Untreated</sub>
###xml 1735 1744 1711 1720 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Untreated</sub>
###xml 1807 1808 1783 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Ewing's sarcoma cell lines, A4573 and CHP100, and the DSRCT cell line, JN-DSRCT-1, were seeded (5x104 cells/well) in 24-well plates and allowed to adhere for 24 hrs prior to treatments with increasing doses (0.01 to 10 microM) of doxorubicin or various nucleoside analogs, 2-Chloro-2'-deoxyadenosine (2-CdA, also known as cladribine), 2-Fluoroadenine-9-beta-D-arabinofuranoside (F-ara-A, also known as fludarabine), and 5-fluorouracil (5-FU). All chemicals were purchased from Sigma-Aldrich. For an acidic culture condition, DMEM-F12 medium (pH 7.4) was adjusted to pH 6.6 by the addition of non-essential amino acids (100x, Invitrogen). The cytotoxicity of various drugs were measured using the Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc. Gaithersburg, MD), a variant of an MTT assay which measures the conversion of a substrate to a water soluble formazan salt by sepctrophotometric quantification at 450 nm [44]. Dose-response curve and standard deviation were determined from three independent experiments performed in duplicate. For siRNA knockdown experiments, 3x105 of JN-DSRCT-1 cells were seeded in 12-well plate and transfected with 100 pmol of each siRNA using Lipofectaminetrade mark 2000 (Invitrogen). Twenty-four hours post-transfection, cells were treated with either 1 microM of 2-CdA or 10 microM of F-ara-A at pH 6.6 for another 48 hrs. The knockdown efficiency of EWS/WT1 was confirmed by western blotting. The cytotoxicity was assessed by an independent method using ToxiLight BioAssay Kit (Lonza, Rockland, ME), which quantitatively measures the release of adenylate kinase (AK) from damaged cells [45]. The percent AK release was calculated using the following formula: (RLUTreated-RLUUntreated)/RLUUntreatedx100, where RLU represents the relative luminescence unit. All p values were calculated using one-way ANOVA analysis followed by Tukey's multiple comparison test.
###end p 66
###begin title 67
Supporting Information
###end title 67
###begin p 68
Quantitative RT-PCR analysis of EWS/WT1(+KTS) and EWS/WT1(-KTS) expression in UED5 and UF5 cells. Quantitative RT-PCR analysis of EWS/WT1(-KTS) and EWS/WT1(+KTS) expression in UF5 and UED5 cells. Total RNA was isolated from UF5 and UED5 cells grown in the presence or absence of tetracycline (Tet) for 14 hrs and expression of EWS/WT1 in the absence of Tet was quantified by SYBR Green PCR and expressed as relative to the level in the uninduced (+Tet). GAPDH was amplified as a reference normalization control.
###end p 68
###begin p 69
(0.39 MB TIF)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin p 71
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
Expression of ENT4 in human cancer cell lines. Quantative RT-PCR analysis of ENT4 in human cancer cell lines. Total RNA was isolated from two human prostate cancer cell lines, DU-145 and PC3, an osteosarcoma cell line U2OS, and the JN-DSRCT-1 cell line, and the expression level of ENT4 was quantified by quantitative RT-PCR using assay-on-demand TaqMan ENT4 and GAPDH probes (Applied Biosystems, Foster City, CA). Data were analyzed by comparative Ct method using Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) as an endogenous control. The expression level of ENT4 in DU-145 cells was arbitrarily set to a reference value of 1 and used to compare the level of ENT4 expression in other cell lines.
###end p 71
###begin p 72
(0.42 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
We thank Dr. Jun Nishio (Fukuoka University, Fukuoka, Japan) for providing the JN-DSRCT-1 cells and Dr. Crystal Mackall (NCI, NIH) for the Ewing sarcoma cell lines.
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants.
###end article-title 76
###begin article-title 77
Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals.
###end article-title 77
###begin article-title 78
Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors.
###end article-title 78
###begin article-title 79
The EWS-WT1 gene fusion in desmoplastic small round cell tumor.
###end article-title 79
###begin article-title 80
Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor.
###end article-title 80
###begin article-title 81
Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.
###end article-title 81
###begin article-title 82
###xml 81 86 <span type="species:ncbi:9606">human</span>
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.
###end article-title 82
###begin article-title 83
hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II.
###end article-title 83
###begin article-title 84
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
###end article-title 84
###begin article-title 85
The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains.
###end article-title 85
###begin article-title 86
Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development.
###end article-title 86
###begin article-title 87
###xml 91 100 <span type="species:ncbi:7955">zebrafish</span>
Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo.
###end article-title 87
###begin article-title 88
Wilms' tumour: connecting tumorigenesis and organ development in the kidney.
###end article-title 88
###begin article-title 89
Wilms tumor and the WT1 gene.
###end article-title 89
###begin article-title 90
The WT1 Wilms' tumor suppressor gene: how much do we really know?
###end article-title 90
###begin article-title 91
Alternative splicing and genomic structure of the Wilms tumor gene WT1.
###end article-title 91
###begin article-title 92
Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence.
###end article-title 92
###begin article-title 93
The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct.
###end article-title 93
###begin article-title 94
The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties.
###end article-title 94
###begin article-title 95
The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour.
###end article-title 95
###begin article-title 96
Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein.
###end article-title 96
###begin article-title 97
Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product.
###end article-title 97
###begin article-title 98
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis.
###end article-title 98
###begin article-title 99
A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round-cell tumor.
###end article-title 99
###begin article-title 100
Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein.
###end article-title 100
###begin article-title 101
Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH.
###end article-title 101
###begin article-title 102
Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells.
###end article-title 102
###begin article-title 103
###xml 76 81 <span type="species:ncbi:9606">human</span>
Identification and characterization of a novel monoamine transporter in the human brain.
###end article-title 103
###begin article-title 104
The equilibrative nucleoside transporter family, SLC29.
###end article-title 104
###begin article-title 105
###xml 46 51 <span type="species:ncbi:9606">human</span>
Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1.
###end article-title 105
###begin article-title 106
Renal nucleoside transporters: physiological and clinical implications.
###end article-title 106
###begin article-title 107
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
###end article-title 107
###begin article-title 108
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.
###end article-title 108
###begin article-title 109
The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.
###end article-title 109
###begin article-title 110
The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.
###end article-title 110
###begin article-title 111
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes.
###end article-title 111
###begin article-title 112
Why do cancers have high aerobic glycolysis?
###end article-title 112
###begin article-title 113
Growth regulation of the vascular system: an emerging role for adenosine.
###end article-title 113
###begin article-title 114
Mammalian nucleoside transporters.
###end article-title 114
###begin article-title 115
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
###end article-title 115
###begin article-title 116
Newer purine analogues for the treatment of hairy-cell leukemia.
###end article-title 116
###begin article-title 117
Nucleoside analogues and nucleobases in cancer treatment.
###end article-title 117
###begin article-title 118
Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development.
###end article-title 118
###begin article-title 119
###xml 13 18 <span type="species:ncbi:9606">human</span>
Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections.
###end article-title 119
###begin article-title 120
###xml 58 63 <span type="species:ncbi:9606">human</span>
Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.
###end article-title 120
###begin p 121
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 121
###begin p 122
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by the Intramural Research Program of the NIH, NIDDK (S.B.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 122

